This thesis review discusses the pharmacological treatment of Renal Cell Carcinoma, which is the most fatal urological malignancy. Drugs such as Bevacizumab, Sorafenib, Cabozantinib, Sunitinib, Tivozanib, Pazopanib, Lenvatinib, Axitinib, Everolimus, Ipilimumab, Nivlomumab, Aldesleukin and Belzutifan are discussed including their mechanism of action, pharmacokinetics, safety and clinical trials in Renal Cell Carcinoma.